212 related articles for article (PubMed ID: 10066147)
1. Use of the PFA-100 in the assessment of primary, platelet-related hemostasis in a pediatric setting.
Rand ML; Carcao MD; Blanchette VS
Semin Thromb Hemost; 1998; 24(6):523-9. PubMed ID: 10066147
[TBL] [Abstract][Full Text] [Related]
2. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
[TBL] [Abstract][Full Text] [Related]
3. PFA-100 system: a new method for assessment of platelet dysfunction.
Mammen EF; Comp PC; Gosselin R; Greenberg C; Hoots WK; Kessler CM; Larkin EC; Liles D; Nugent DJ
Semin Thromb Hemost; 1998; 24(2):195-202. PubMed ID: 9579642
[TBL] [Abstract][Full Text] [Related]
4. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders.
Favaloro EJ; Facey D; Henniker A
Am J Hematol; 1999 Nov; 62(3):165-74. PubMed ID: 10539883
[TBL] [Abstract][Full Text] [Related]
5. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children.
Carcao MD; Blanchette VS; Dean JA; He L; Kern MA; Stain AM; Sparling CR; Stephens D; Ryan G; Freedman J; Rand ML
Br J Haematol; 1998 Apr; 101(1):70-3. PubMed ID: 9576184
[TBL] [Abstract][Full Text] [Related]
6. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
7. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center.
Ortel TL; James AH; Thames EH; Moore KD; Greenberg CS
Thromb Haemost; 2000 Jul; 84(1):93-7. PubMed ID: 10928477
[TBL] [Abstract][Full Text] [Related]
8. The platelet function analyzer (PFA-100): an update on its clinical use.
Franchini M
Clin Lab; 2005; 51(7-8):367-72. PubMed ID: 16122146
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of primary hemostasis in neonates with a new in vitro platelet function analyzer.
Israels SJ; Cheang T; McMillan-Ward EM; Cheang M
J Pediatr; 2001 Jan; 138(1):116-9. PubMed ID: 11148524
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease.
Schlammadinger A; Kerenyi A; Muszbek L; Boda Z
Thromb Haemost; 2000 Jul; 84(1):88-92. PubMed ID: 10928476
[TBL] [Abstract][Full Text] [Related]
11. Closure times measured by the platelet function analyzer PFA-100 are longer in neonatal blood compared to cord blood samples.
Saxonhouse MA; Garner R; Mammel L; Li Q; Muller KE; Greywoode J; Miller C; Sola-Visner M
Neonatology; 2010; 97(3):242-9. PubMed ID: 19887853
[TBL] [Abstract][Full Text] [Related]
12. Hemostatic function in healthy pregnant and preeclamptic women: an assessment using the platelet function analyzer (PFA-100) and thromboelastograph.
Davies JR; Fernando R; Hallworth SP
Anesth Analg; 2007 Feb; 104(2):416-20. PubMed ID: 17242101
[TBL] [Abstract][Full Text] [Related]
13. External quality assessment/proficiency testing and internal quality control for the PFA-100 and PFA-200: an update.
Favaloro EJ; Bonar R
Semin Thromb Hemost; 2014 Mar; 40(2):239-53. PubMed ID: 24497116
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.
Cattaneo M; Federici AB; Lecchi A; Agati B; Lombardi R; Stabile F; Bucciarelli P
Thromb Haemost; 1999 Jul; 82(1):35-9. PubMed ID: 10456451
[TBL] [Abstract][Full Text] [Related]
15. PFA-100 closure times in preoperative screening in 500 pediatric patients.
Roschitz B; Thaller S; Koestenberger M; Wirnsberger A; Leschnik B; Fritsch P; Muntean W
Thromb Haemost; 2007 Jul; 98(1):243-7. PubMed ID: 17598019
[TBL] [Abstract][Full Text] [Related]
16. [New in vitro analysis tested: bleeding time is still the best method for evaluation of primary hemostasis].
Ridefelt P; Egberg N; Hillarp A; Lethagen S; Tengborn L
Lakartidningen; 2001 Sep; 98(37):3922-4. PubMed ID: 11586831
[TBL] [Abstract][Full Text] [Related]
17. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Giannini S; Mezzasoma AM; Leone M; Gresele P
Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
[TBL] [Abstract][Full Text] [Related]
18. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals.
Haubelt H; Anders C; Vogt A; Hoerdt P; Seyfert UT; Hellstern P
Br J Haematol; 2005 Sep; 130(5):759-67. PubMed ID: 16115134
[TBL] [Abstract][Full Text] [Related]
19. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults.
Harrison P
Br J Haematol; 2005 Jul; 130(1):3-10. PubMed ID: 15982339
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of primary haemostasis in people with neurofibromatosis type 1.
Favaloro EJ; Zafer M; Nair SC; Hertzberg M; North K
Clin Lab Haematol; 2004 Oct; 26(5):341-5. PubMed ID: 15485464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
